Low-Dose BCMA CAR-T Therapy Anito-Cel Eradicates Myeloma in All 38 Phase 1 Patients

Patients with relapsed or refractory multiple myeloma have long faced a grim arithmetic: each successive round of therapy works less well than the last, until eventually no effective option remains. A phase 1 clinical trial led by investigators at Mass General Brigham Cancer Institute and the University of Chicago Medicine Comprehensive Cancer Center now offers a striking new data point in that struggle. The trial tested anitocabtagene autoleucel, known as anito-cel, an investigational CAR-T cell therapy engineered to target BCMA, a protein displayed on the surface of myeloma cells. In results published in The New England Journal of Medicine, all 38 treated participants responded to the single infusion, and nearly 80 percent achieved a complete response, meaning no detectable evidence of the disease remained. For a phase 1 study, a stage where experimental treatments are primarily vetted for safety rather than expected to produce uniformly dramatic outcomes, the response profile was remarkable enough that the investigators themselves emphasized how unusual it was. Even at the low dose administered in the trial, complete responses appeared in the majority of patients, and none developed severe toxicities.

The durability of those responses is as consequential as their depth. Multiple myeloma is a cancer of plasma cells, the antibody-producing arm of the immune system, and it is notorious for relapsing after initially effective treatment. The anito-cel trial therefore tracked patients well beyond the initial response window. More than half of the participants remained progression-free two years after receiving the therapy, and 65 percent were still alive three years out. In a population whose disease had already resisted multiple prior lines of therapy, those figures suggest that a single treatment can reset the course of the disease for a meaningful fraction of patients rather than merely buying time between relapses. Long-term follow-up from larger trials will be needed to determine how many of these responses endure indefinitely, but the trajectory of the phase 1 cohort provides the kind of early evidence that cellular therapy researchers look for when deciding whether a new construct deserves expansion into pivotal testing.

Equally important to the efficacy numbers was the safety picture, which distinguished anito-cel from earlier generations of BCMA-directed CAR-T therapies. Serious immune-related and neurological side effects were uncommon in the trial, and no delayed neurological complications were reported at all. That last point matters because some existing CAR-T cell therapies targeting BCMA have been linked to rare but serious neurological side effects, including delayed syndromes that can emerge weeks after infusion and cause lasting impairment. Patients with relapsed or refractory myeloma already endure substantial treatment burden, and the prospect of a therapy whose most feared complications appear to be largely absent represents a genuine shift in the risk-benefit calculation. The investigators reported that the absence of neurotoxic and inflammatory side effects was particularly encouraging given the serious and potentially lasting impact such complications can have on patients’ lives.

The apparent explanation lies in the molecular design of the construct itself. CAR-T therapy begins with a patient’s own T cells, which are extracted, genetically engineered to recognize a specific target on cancer cells, multiplied in the laboratory, and infused back into the patient. The recognition element, called the binding domain, determines both how effectively the engineered cells kill cancer and how vigorously they activate the immune system. Excessive activation drives the inflammatory toxicities that have shadowed CAR-T therapy since its inception, including cytokine release syndrome and neurotoxicity. According to the researchers’ laboratory analyses, anito-cel’s engineered BCMA-binding domain, described as a novel D-domain binder, maintained the cancer-killing activity required for efficacy while limiting the excessive immune activation and other features that can impair CAR-T cell function or contribute to toxicity. In other words, the design appears to have decoupled potency from inflammation, a goal that has eluded many previous construct engineering efforts.

Senior author Michael R. Bishop, MD, Professor of Medicine and Director of the David and Etta Jonas Center for Cellular Therapy at UChicago Medicine, framed the findings in the context of what phase 1 trials usually deliver. He described the results as great for a phase 1 study, noting that even at a low dose of anito-cel the team was seeing complete responses in the majority of patients right away, and that not a single patient developed severe toxicities. That combination, he said, prompted the investigators to investigate further why the safety profile was so favorable. Lead author Matthew Frigault, MD, vice chair of Clinical Research in Hematology/Oncology and deputy program director of the Cellular Immunotherapy Program at the Mass General Brigham Cancer Institute, highlighted the absence of neurotoxic and inflammatory side effects as particularly encouraging, and suggested that the novel D-domain binder may contribute to that finding. He added that the combination of compelling efficacy and encouraging safety data lays important groundwork for continuing to investigate this new treatment option for patients.

To understand why a BCMA-targeted therapy is so significant for myeloma specifically, it helps to consider the biology of the disease. BCMA, or B-cell maturation antigen, is a surface protein expressed on myeloma cells and largely restricted to the late B-cell lineage, which makes it an attractive bullseye: attacking it spares most healthy tissue while striking the malignant plasma cells directly. Two BCMA-directed CAR-T products are already approved for myeloma, and they have demonstrated that redirecting T cells against this target can produce deep remissions. The field’s outstanding questions concern durability, accessibility, and above all toxicity. The delayed neurological syndromes associated with some BCMA constructs, along with the cytokine-driven inflammatory storms that can accompany infusion, have constrained how these therapies are used and pushed clinicians to weigh carefully which patients should receive them. A construct that preserves efficacy while reducing these risks could widen the population for whom CAR-T therapy is a reasonable choice.

The trial itself was a phase 1 study, the first step in the clinical evaluation pathway, typically designed to establish dosing and identify side effects in a small cohort rather than to prove efficacy against a control group. That all 38 participants responded is not a randomized comparison, and phase 1 results by definition come with caveats about patient selection and cohort size. The investigators and the therapy’s developer, Kite, a Gilead company, have responded to the results in the standard way: anito-cel is currently being evaluated in phase 2 and phase 3 clinical trials intended to confirm the findings in larger populations of patients with multiple myeloma. Those pivotal studies will subject the construct to the scrutiny of broader enrollment, longer follow-up, and, in some designs, direct comparison against existing standards of care, which is the evidence regulators require before approving a new therapy.

The study also illustrates the growing sophistication of CAR-T engineering as a discipline. Early CAR-T constructs were largely borrowed from antibody fragments grafted onto T-cell signaling machinery, and the field learned through experience that the fine details of the binding domain, including its affinity, the geometry of its engagement with the target, and the signaling architecture it feeds into, profoundly shape the behavior of the resulting cells. The D-domain binder characterized in this trial reflects a deliberate design strategy: rather than accepting whatever toxicity profile a construct happens to produce, researchers are now engineering the recognition module itself to tune immune activation downward while preserving cytotoxic function. The laboratory analyses accompanying the clinical results, in which the researchers characterized the binder’s properties, point toward a future in which CAR-T products are designed with toxicity management built in at the molecular level rather than managed afterward with supportive drugs.

For patients and their physicians, the practical meaning of the trial is straightforward. Multiple myeloma remains incurable with current approaches, and treatment typically proceeds through a sequence of proteasome inhibitors, immunomodulatory drugs, antibody therapies, and eventually BCMA-directed options, each of which the disease may eventually evade. Anito-cel’s phase 1 data indicate that a next-generation BCMA CAR-T may deliver deep, durable remissions even in patients whose myeloma has already exhausted many prior therapies, with a safety profile that avoids the delayed neurological complications that have made some existing products difficult to deploy. The investigators caution that confirmation in larger trials is essential, and the ongoing phase 2 and phase 3 studies will determine whether the striking phase 1 experience holds up at scale. But the results, published in The New England Journal of Medicine under the title describing anito-cel as a D-domain BCMA CAR-T with phase 1 results and binder characterization, establish a credible new candidate in the cellular therapy pipeline for one of hematologic oncology’s most persistent challenges, and they demonstrate that rational engineering of the binding domain can translate into measurable clinical benefit at the bedside.

Subject of Research: A phase 1 trial of the BCMA-targeted CAR-T cell therapy anito-cel for relapsed or refractory multiple myeloma

Article Title: Novel CAR-T therapy shows promising safety and durable responses in hard-to-treat multiple myeloma

Article References: Novel CAR-T therapy shows promising safety and durable responses in hard-to-treat multiple myeloma. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: multiple myeloma, CAR-T cell therapy, anito-cel, BCMA, phase 1 clinical trial, immunotherapy, D-domain binder, neurotoxicity, Mass General Brigham, University of Chicago Medicine, New England Journal of Medicine, relapsed refractory cancer